Recently, four second-generation chimeric antigen receptor (CAR) T cell therapy products tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, and lisocabtagene maraleucel targeting CD19 antigen have been approved by the FDA for the treatment of B-cell lymphoma [9,10]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.